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Abstract
The availability of human neuronal progenitors (hNPs) in high purity would greatly facilitate neuronal drug discovery and
developmental studies, as well as cell replacement strategies for neurodegenerative diseases and conditions, such as spinal
cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Here we describe for the first time a
method for producing hNPs in large quantity and high purity from human embryonic stem cells (hESCs) in feeder-free
conditions, without the use of exogenous noggin, sonic hedgehog or analogs, rendering the process clinically compliant.
The resulting population displays characteristic neuronal-specific markers. When allowed to spontaneously differentiate into
neuronal subtypes in vitro, cholinergic, serotonergic, dopaminergic and/or noradrenergic, and medium spiny striatal
neurons were observed. When transplanted into the injured spinal cord the hNPs survived, integrated into host tissue, and
matured into a variety of neuronal subtypes. Our method of deriving neuronal progenitors from hESCs renders the process
amenable to therapeutic and commercial use.
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Introduction
Central to the use of pre-differentiated cells for screening or
transplantation is the purity of the cell population. Cell sorting
requires that the desired cells be labeled with fluorescent
antibodies to phenotype-specific cell surface proteins, or engi-
neered to express a fluorescent protein under the control of a
phenotype-specific promoter. Both techniques have potential
drawbacks: immunodetection necessitates further digestion of cell
surface proteins to remove the antibody label, and reporter gene
expression requires genetic manipulation of the starting popula-
tion. Both of these sorting methods require time, which allows for
amplification of contaminant populations. Regardless of the
technique, the purity of the sorted population is dependent on
the specificity of the label or reporter used. In the event that a cell-
specific promoter is available, a conjunctional method is the
knock-in of a gene for a foreign protein such as green fluorescent
protein under the control of the promoter to highlight the cells for
selection. However, the tumorigenic risk posed by insertion
methods renders the use of reporter genes or any cell-specific
selection genes, such as antibiotic resistance genes, undesirable for
clinical use as per current US FDA guidelines. Lastly, the small
yield of sorting methods limits the commercial or clinical viability
of the approach. Nonetheless, these sorting methods are very
useful for the production of small scale research grade cell
populations.
Several groups have described the derivation of neural
progenitors from hESCs, which are capable of differentiating into
neuronal and glial cell types; indeed, neural induction appears to
be the default path from hESC [1,2,3,4]. Neuronal progenitors are
more lineage-specific than neural progenitors, as they do not
differentiate into oligodendrocytes and astrocytes. Human neurons
and neuronal progenitors are difficult to obtain from primary
culture of harvested tissue, and impossible to obtain in large
quantities for clinical and commercial application. As there is
growing application of human stem cell technologies in the
biopharmaceutical sector, the availability of human neuronal
progenitors (hNPs) in high purity would greatly facilitate neuronal
drug discovery and lead developmental studies. In addition,
cell replacement strategies for neurodegenerative diseases and
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purity hNPs.
Here we describe for the first time a method for producing hNPs
in large quantity and high purity from hESCs in serum-free and
feeder-free conditions, without the use exogenous noggin or sonic
hedgehog. With appropriate quality and manufacturing control,
this method could produce clinical grade hNPs in sufficient
quantity for use in biopharmaceutical research and developmental
studies, as well as therapeutic strategies addressing diseases and
conditions characterized by the loss of neurons.
Materials and Methods
Ethics Statement
All animal work for this study was approved (approval ID
number 2007–2725) and carried out in accordance with the UCI
Institutional Animal Care and Use Committee. Animals received
appropriate post-surgical care including subcutaneous saline,
prophylactic Baytril (2.5 mg/kg/d, s.c.; Bayer, Shawnee Mission,
KS), and Buprenorphine (0.025 mg/kg/d, s.c.; Western Medical
Supply, Los Angeles, CA) for three days. Animals were inspected
for weight loss, dehydration, discomfort, and autophagia, with
appropriate veterinary care as needed. All work involving human
embryonic stem cells was approved by the UCI Human
Embryonic Stem Cell Research and Oversight Committee
(2007–5645).
Differentiation of hNPs from hESCs
hNPs were derived from hESC lines H7, hCSC14 and
hCSC14-CL1 (California Stem Cell, Inc., Irvine, CA) at passages
15–17. hESC cultures were expanded on Matrigel (BD Bioscienc-
es, San Jose, CA) or a defined substrate, CellGel (California Stem
Cell, Inc., Irvine, CA). StemBlast (California Stem Cell, Inc.,
Irvine, CA) was used to feed the cultures daily and was
supplemented with 10 ng bFGF/ml/day as previously described
[5]. When cultures attained .75% confluence, cells were removed
from the adherent substrate, transferred to ultra low binding
75 cm
2 or 225 cm
2 or 630 cm
2 dishes (Corning, NY) and
suspended in NeuroBlast media (California Stem Cell, Inc.,
Irvine, CA), a DMEM-F12 based media absent of bone
morphogenic proteins and pluripotenfig.cy sustaining factors, that
induces ectodermal commitment. NeuroBlast media was modified
by addition of Glutamax (Invitrogen, Carlsbad, CA) diluted to 16
from stock, and B27 supplement (Invitrogen, Carlsbad, CA)
diluted to 16 from stock. FGF (Millipore, Billerica, MA) and
retinoic acid (all-trans-retinoic acid; RA; Sigma Aldrich, St. Louis,
MO) was added to the cultures at a final concentration of 10 mM
in DMSO daily for 5 days. After the RA treatment, the cultures
were fed every second day, and FGF was reduced from 10 ng/ml
to 5 ng/ml. The feeding procedure consisted of a 3–5 minute
gravity selection of the dense cell clusters in a column (50 ml
centrifuge tube) followed by complete replacement of the
supernatant, which contained the cell clusters of lesser density.
At day 18, the cultures were plated on Matrigel or CellGel and left
to spontaneously differentiate for two days. At day 20, the cells
were dissociated again. Cells were then either 1) replated into
flasks and maintained for up to 3 weeks with no addition of growth
factors for polymerase chain reaction (PCR) analysis of gene
expression, 2) were plated into 96-well plates at a density of 10,000
and 40,000 cells per well and maintained for 3 weeks by 2/3
media replacement every 2
nd day in order to assess the
spontaneous differentiation into neuronal subtypes via immuno-
cytochemistry, or 3) were plated into 96-well plates with
manipulated culture conditions and maintained for 3 weeks in
order to assess the altered differentiation into neuronal subtypes
via immunocytochemistry. During the 3 week period of spon-
taneous differentiation, no growth factors were added to the
cultures. For the 3 week period of manipulated differentiation,
NeuroBlast media was modified with RA free B27 supplement and
the addition of either FGF8 (10 ng/ml), FGF2 (10 ng/ml), BDNF
(10 ng/ml), GDNF (10 ng/ml), or Activin A (5 ng/ml).
Immunocytochemical Labeling
For hNP identification and neuronal subtyping, cultures were
fixed with 4% paraformaldehyde for one hour, blocked with 5%
serum, and then exposed to primary antibodies anti-nestin 1:200,
anti-TUJ1 1:400, anti-ChAT 1:200, anti-O4 1:200, anti-MAP2
1:200, anti-Musashi-1 1:200, anti-GABAA Receptor a1 1:200
(Chemicon, Temecula, CA/Millipore, Billerica, MA), anti-GFAP
1:500 (Sigma), anti MNR2 (HB9) 1: 100 (Developmental Studies
Hybridoma Bank, Iowa City, IA), anti-Tau 1:200, anti-DARPP32
1:200 (Cell Signaling Technology, Danvers, MA), anti-Ki67
1:1000 (DAKO, Carpinteria, CA), anti-doublecortin 1:200, anti-
PDGF-a 1:200, anti-NG2 1:200 (Santa Cruz Biotechnology, Santa
Cruz, CA), anti-tyrosine hydroxylase 1:200, anti-5HT 1:200
(Abcam, Cambridge, MA) at 4uC overnight. Primary antibody
application was followed by fluorescent secondary antibodies
(Alexafluor-594 or Alexafluor-488 conjugated; Invitrogen, Carls-
bad, CA), and visualized with fluorescence microscopy according
to standard protocols.
Dividing cells were labeled using a BrdU labeling and detection
kit (Roche, Mannheim, Germany). Briefly, adherent cells at 50%
confluency were incubated with BrdU labeling medium for 1 hour
at 37uC, then washed 3 times prior to fixation. Mouse anti-BrdU
working solution was then applied to fixed cells and incubated for
30 minutes at 37uC. After washing 3 times, cells were incubated
with mouse anti-IgG solution for 30 minutes at 37uC. Cells were
then washed, mounted, and visualized with fluorescent microscopy.
Real-Time Polymerase Chain Reaction
RNA from hNPs that were allowed to spontaneously differentiate
was harvested every seven days for three weeks after the hNP
differentiation protocol (Days 7, 14, and 21 days after hNP
differentiation). Cells were collected after trypsinization with 0.25%
trypsin EDTA and total RNA was extracted using the RNeasy kit
and RNase-free DNase set (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. RNA concentrations were measured
with the NanoDrop ND-8000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE). One microgram (1 mg) of total
RNA was reverse transcribed using RT
2 First Strand Kit
(SABiosciences, Frederick, MD) according to the manufacturer’s
instructions. This kit contains a procedure to eliminate contami-
nating genomic DNA from RNA samples before reverse transcrip-
tion. cDNA was then assayed on a human neurogenesis and neural
stem cell RT
2 profiler PCR array (SABiosciences, Frederick, MD)
which profiles 84 genes related to the processes of neurogenesis and
neural stem cell differentiation. Real-time polymerase chain
reaction (PCR) measurements were performed on an ABI PRISM
7900HT Sequence Detector System (Applied BioSystems, Foster
City, CA, http://www.appliedbiosystems.com).
Gene expression that changed by 8-fold, as determined by the
DDCt method is reported.
Spinal Cord Injury and Transplantation
All animal work was carried out in accordance with the UCI
Institutional Animal Care and Use Committee (2007–2725).
Adult, female Sprague-Dawley rats (Charles River Laboratories;
San Diego, CA) underwent a laminectomy at C5–C6 and received
High Purity Neuronal Progenitors from Stem Cells
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Impactor (Precision Systems and Instruments; Lexington, KY).
Seven days later, the laminectomy site was re-exposed, the animals
were secured to a stereotactic apparatus, and 100,000 hNP cells in
total were transplanted into the spinal cord. Cells were injected
bilaterally cranial and caudal to the injury site using a 33G needle
attached to a Hamilton syringe at 25,000 cells/uL. One day prior
to transplant, the animals received cyclosporine A (20 mg/kg/d,
s.c.; Bedford Laboratories, Bedford, OH), which was then
continued for the duration of the protocol. In addition, animals
received 0.5 mg/kg Rolipram (A.G. scientific; San Diego, CA)
subcutaneously from 2 days prior to transplant and for thirty days
thereafter.
hNP cells were dissociated from adherent conditions the night
prior to transplantation. The cells were then plated into a non-
adherent flask to form microspheres. The cells were collected and
spun at 100rcf. The pellet was resuspended in Cell Transplant
Solution (CTS; California Stem Cell, Inc., Irvine, CA) and 2 more
centrifugations and resuspensions were performed to wash
the hNP microspheres. This method was performed to remove
non-viable cells.
Histology
All animals were sacrificed 3 months post-transplant via trans-
cardiac perfusion with 4% paraformaldehyde. The tissue was
cryopreserved in 27% sucrose and the cords were sectioned into
1 mm blocks and embedded in OCT compound. Tissue was
cryosectioned at 20 um and mounted onto gelatin coated slides. To
determine the fate of the transplanted hNP cells, the tissue was
labeled for human nuclei 1:200 (Abcam, Cambridge, MA), TUJ1
1:1000 (Covance, Princeton, NJ), doublecortin 1:200 (Santa Cruz
Biotechnology, Santa Cruz, CA), ChAT 1:100 (Millipore,
Temecula, CA), GAD 65–67 1:500 (Abcam, Cambridge, MA),
anti-p75 neurotrophin receptor 1:200 (Santa Cruz Biotechnology,
Santa Cruz, CA), 5-HT 1:200 (Abcam, Cambridge, MA), NCAM
1:500 (Santa Cruz Biotechnology, Santa Cruz, CA) and synapto-
physin 1:200 (Abcam, Cambridge, MA). Secondary AlexaFluor
antibodies (Invitrogen, Carlsbad, CA) against primary antibody
species were used for fluorescent imaging, and biotinylated
secondary antibodies were used with DAB reaction for light
microscopy imaging.
Results
In Vitro Differentiation Profile
At day 14 of the 21-day differentiation protocol, free-floating
cultures consisted of solid core neurospheres (Fig. 1a). Following
plating of neurospheres, neuroepithelial cells were identified by
their characteristic morphology at days 16–18 of differentiation
(Fig. 1b). Immunocytochemical staining revealed extensive
expression of the RNA binding protein, Musashi-1, which was
observed in 99.2% of cells (Fig. 1c), and nestin (red) in 98.8% of
cells (Fig. 1d), indicating that the culture consisted of high purity
neural progenitor cells. Co-expression of TUJ1 (green) in some of
the nestin (red) positive cells, and the presence of typical neurites
on all cells, further suggested the differentiation of the cultures
towards neuronal types (Fig. 1d). No cells labeled with NG2 or
PDGF-a, indicating that cultures did not contain cells of the
oligodendroglial lineage.
As gross observation of cultures suggested continuous expansion
of the cultures, we investigated the proliferative potential of the
hNPs. Our culture and passage conditions did not group dividing
cells in neural rosettes as is common for other culture conditions,
but rather, proliferating cells were homogenously dispersed. The
proliferation marker Ki67 was observed in 26.4% of cells (Fig. 1e)
and BrdU labeling was observed in 28.6% of cells (data not
shown). Doublecortin, the microtubule-associated protein that is
expressed by the neuronal lineage, was detected in 91.2% of the
cells (Fig. 1f), further supporting the interpretation that our
cultures consisted of high purity neuronal progenitors. Consistent
with our Ki67 and BrdU data, the amount of RNA extracted from
cultures was increased by 28.4% after 7 days of spontaneous
differentiation in growth factor free media (after day 21 of
neuronal progenitor differentiation), indicative of cell proliferation.
The spontaneous differentiation potential of this cell population
was assessed by immunocytochemical and RNA expression
analyses after 3 weeks in growth factor free conditions. hNP-
derivates displayed a highly branched morphology (Fig. 2a).
Immunocytochemical staining confirmed neuronal maturation;
96.2% of cells expressed TUJ1 (green; Fig. 2b), 95.4% of cells
expressed the microtubule-associated protein Tau (Fig. 2c), and
80.5% of cells expressed the neuron-specific microtubule associ-
ated protein MAP2 (Fig. 2d). 4.1% of cells expressed GFAP (red;
Fig. 2b). Choline acetyltransferase (ChAT) expression was detected
in 97% of cells, demonstrating that the majority of hESC-derived
hNPs have the potential to become cholinergic neurons (Fig. 3a).
GABAA receptor a1 expression was detected in 87% of hNP-
derivates, demonstrating the capability to become GABA-
responsive neurons (Fig. 3c). hNP-derivates also demonstrated
the ability to become other neuronal subtypes, as evidenced by
their expression of 5-HT (3%; Fig. 3b), tyrosine hydroxylase (1%;
Fig. 3d), and DARPP32 (2%; Fig. 3e). A small percentage of cells
(4.1%) expressed the astrocyte marker GFAP (Fig. 2b, 3f). No cells
were labeled with 04, indicating that cultures did not contain cells
of the oligodendroglial lineage. ,0.1% of cells were unlabeled.
Based on morphology, size, ChAT and GABAA receptor a1
expression expression, we conclude that most of the cells that
resulted from spontaneous differentiation of high purity NPs were
motor neuron progenitors.
In these growth factor free conditions, RNA analyses indicated
that hNP-derivates up-regulated expression of brain-derived
neurotrophic factor (BDNF), neuronal cell adhesion molecule
(NCAM), and sonic hedgehog (SHH) by 8-fold as compared to
undifferentiated hNPs (after the 21 day differentiation protocol;
Fig. 4a). The muscarinic cholinergic receptor 2 (CHRM2),
dopamine receptor D1 (DRD1), fibroblast growth factor 13
(FGF13), ionotropic N-methyl D-aspartate glutamate receptor 1
(GRIN1), neurogenic differentiation 1 (NEUROD1), and odz, odd
Oz/ten-m homolog 1 (ODZ1) were up-regulated by 10-fold as
compared to undifferentiated hNPs (after the 21 day differentia-
tion protocol; Fig. 4a). This RNA expression profile is consistent
with neuronal differentiation.
In these growth factor free conditions, RNA analyses indicated
that hNP-derivates down-regulated expression of the developmen-
tally regulated S100 Ca(2+)-binding protein family member
S100A6 and the oligodendrocyte marker SOX8 by 8-fold as
compared to undifferentiated hNPs (after the 21 day differentia-
tion protocol; Fig. 4b). This RNA expression profile is consistent
with developmental maturation of the neuronal lineage.
In Vivo Differentiation Profile
The differentiation potential of hNPs was further analyzed by
assessing their phenotype 3 months following transplantation into
sites of spinal cord injury. Immunohistochemical analyses
indicated that anti-human nuclei positive cells co-localized with
the neuronal specific markers TUJ1 (Fig. 5a) and doublecortin
(Fig. 5b). Neuronal subtype specific differentiation was evidenced
by double labeling of anti-human nuclei positive cells with p75
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sympathetic neurons (Fig. 5c), GAD 65–67 consistent with their
differentiation to interneurons (Fig. 5d), and ChAT consistent with
their differentiation to cholinergic neurons (Fig. 5e). NCAM
(green) and synaptophysin (red) double immunolabeling revealed
synapses on anti-human nuclei positive cells (Fig. 5f). This immu-
nohistochemical profile indicates that hNPs have the capability of
differentiating into neuronal subtypes, a process that is likely
controlled by the environmental factors to which they are exposed.
Manipulation of In Vitro Differentiation Profile
The ability of hNPs to differentiate into a variety of neuronal
subtypes in vivo suggested that their differentiation profile could be
manipulated in vitro. The differentiation potential of hNPs was
assessed 3 weeks following various manipulations of culture
conditions. RA–free conditions resulted in a decrease of
DARPP32 expression (B27 and RAfB27 in Fig. 6a; 2.1% and
1.1% respectively). However, the addition of BDNF or GDNF to
RA-free conditions resulted in an increased number of cells
expressing DARPP32 above that seen in control conditions
(BDNF and GDNF in Fig. 6a; 3.1% and 2.5% respectively).
The addition of Activin A to RA-free conditions yielded a similar
percentage of cells expressing DARPP32 to that of RA-containing
condition (Activin A in Fig. 6a; 1.8%). The addition of FGF8 and
FGF2 to RA-free conditions decreased the DARPP32 intensity to
levels below that of RA-free conditions (FGF8 and FGF2 in Fig. 6a;
0.9% and 0.5% respectively).These data demonstrate that hNPs
can differentiate into DARPP32 expressing neurons, consistent
with a medium spiny neuronal phenotype.
Although RA-free conditions (RAfB27 in Fig. 6c) resulted in a
percentage of 5-HT expressing cells that was not different than RA-
containing conditions (B27 in Fig. 6c), the addition of FGF8, FGF2
and BDNF to RA-free conditions led to an increase in the
percentage of 5-HT expressing cells (Fig. 6d). On the other hand,
the addition of GDNF and Activin A to RA-free conditions resulted
in a decrease of 5-HT expressing cells (1.3% and 1.1% respectively).
Double-labeling studies revealed that several 5-HT positive cells
were also ChAT positive (Fig. 6e, f). The addition of FGF8 and
FGF2 to RA-free conditions increased the percentage of ChAT
expressing cells (Fig. 6g), while the addition of BDNF decreased it.
These data demonstrate that hNPs can differentiate into 5-HT
expressing neurons, similar to those found within the raphe dorsalis.
Figure 1. Differentiation of hESCs into neuronal progenitor cells. A) Neurospheres at day 14 of differentiation. B) After plating of
neurospheres, neuroepithelial cells displayed a typical morphology by days 16–18 of differentiation. C) Musashi-1immunolabeling of cells. D) Nestin
(red) and TUJ1 (green) immunolabeling of cells demonstrated a high percentage of co-localization. E) Ki67 immunolabeling revealed that a portion of
hNPs are mitotic. F) Doublecortin immunolabeling revealed a high percentage of new neurons.
doi:10.1371/journal.pone.0020692.g001
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hydroxylase positive (TH) cells, the addition of FGF2 to RA-free
conditions increased the percentage of TH expressing cells (Fig. 6i,
j). These data demonstrate that hNPs can differentiate into TH
expressing neurons, similar to those found within the nigrostriatal
pathway.
Discussion
The promise of hESCs resides in their ability to produce high
purity lineage-specific cell populations that are difficult or
impossible to obtain from primary culture of harvested tissue.
Included in this category are neuronal progenitors, cells of the
central nervous system (CNS) that are sensitive to mechanical and
chemical injuries, do not regenerate following injury, and can not
be recovered from harvested tissue in high purity. Although
several studies document the directed differentiation of neural
progenitors from hESCs, the glial progeny of this population limits
its usefulness in neuronal developmental studies or screening
assays. Here we describe a novel method for producing neuronal
progenitors in large quantity and high purity from hESCs in
feeder-free conditions, without the use of exogenous noggin, Shh
or analogs, rendering the process clinically compliant.
Published protocols for the in vitro differentiation of embryonic
stem cells into neuronal populations have invariably used Shh,
bone-morphogenic protein (BMPs), noggin and Wnts alone or in
combinations, and most of the authors agree that RA in
combination with Shh is a reliable means of differentiating
neuronal progenitors from hESCs, albeit in low purity and limited
yield [6,7,8,9].
The differentiation protocol described here is fundamentally
different from other published protocols in the media composition
and the physical manipulations of the cells during culture. With
regards to media composition, this protocol differs from others in
the concentration and duration of RA exposure, FGF adminis-
tration, and the absence of exogenous Shh. The addition of 5 ng/
ml FGF during the entire differentiation protocol is essential for
high purity hNP cultures; addition of a higher dose of FGF than
used here resulted in delayed differentiation and increased
contamination with astrocytes and/or neural progenitors. The
absence of FGF, or limited exposure to FGF, resulted in
maturation of cells inside of the spheres, leading to dissociation
difficulties after plating, and gross culture heterogeneity. Finally,
the absence of exogenous Shh was a unique feature of this
neuronal progenitor differentiation protocol.
With regards to physical manipulations, the use of non-adherent
conditions at early stages of the differentiation protocol was critical
for the generation of high purity cultures. Others have described
culture on an adherent substrate resulting in the formation of
neural rosettes (Li et al., 2005), and differentiation of low purity
(10–30%) hNPs with contaminants including neural progenitors,
mesodermal lineages, fibroblasts and myoblasts. To further
enhance the purity of the hNP culture, our protocol used daily
gravity feeding during the initial phases of differentiation to select
a population which spontaneously forms neurospheres, and
eliminate single cells which generate non-neuronal contaminant
populations. We attribute the ‘‘spherogenic’’ properties to NCAM
homophilic interactions on the neuronal progenitors’ cell surface,
with agglomeration of the cells resulting in higher density particles
with faster sedimentation. Quantitative PCR analyses indicated
that NCAM was significantly increased at day 14 of the
differentiation protocol (data not shown). We further hypothesize
that neurospheres at this stage of differentiation (12–14 days)
secrete and trap enough endogenous Shh to induce hNP
differentiation without the addition of exogenous Shh. Differen-
tiation of the same hESC cultures without dissociation and feeding
Figure 2. Differentiation of hNPs into neurons after 3 weeks of maturation. A) hNP-derivates displayed a highly branched morphology,
consistent with a neuronal phenotype. B) Immunolabeling with TUJ1 (green) and GFAP (red) revealed a high purity neuronal culture with few
astrocytes. C) Cells were immunopositive for Tau, a microtubule associated protein, consistent with neuronal differentiation. D) Cells were
immunopositive for MAP2, a microtubule associated protein, consistent with neuronal differentiation.
doi:10.1371/journal.pone.0020692.g002
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geneous population of mixed neurons, glial cells, and undifferen-
tiated cells.
The absence of exogenous Shh enhances the clinical compliance
of our hNP protocol, given the association of exogenous Shh with
tumor formation [10,11,12,13] and cancer cell motility/invasive-
ness [14]. As an alternative to the addition of exogenous Shh, our
protocol involved attenuation of a developmentally important
opposing signal to Shh, BMPs. Thus, clearance of BMPs and/or
cells producing BMPs from the cultures would have an effect
similar to the addition of Shh and/or noggin. BMP levels were
attenuated in our culture conditions by elimination of serum and
serum replacement. Serum contains BMPs and dorsal signaling
molecules, and use of serum in culture conditions promotes the
generation of dorsal phenotypes [15].
We also avoided the use of leukemia inhibitory factor (LIF) in
our differentiation protocol to enhance homogeneity of the
culture, as previous findings suggest that LIF and LIF receptors
are implicated in astrocyte differentiation in vivo and in vitro
through STAT3 [16,17,18]. In combination with RA, LIF acts
through an epigenetic mechanism to activate the GFAP promotor
[18]. Although LIF is typically not used in human cultures as it is
used in mouse embryonic stem cell cultures, it is possible that
embryonic feeders could secrete various factors, including LIF, or
that the presence of other cell types could directly induce astrocytic
differentiation. In co-cultures of undifferentiated stem cells with
endothelial cells or media previously exposed to endothelial
cultures, neuronal differentiation was inhibited [19], likely due to
secretion of LIF [20]. Thus the presence of LIF in other attempts
to derive neuronal cell types likely predisposes those populations
towards glial phenotypes when exposed to RA.
hNPs expressed Musashi-1, nestin, TUJ1 and doublecortin,
markers consistent with a neuronal progenitor phenotype.
Mushashi-1 is a member of the highly conserved Musashi family
of RNA-binding proteins, and is expressed at high levels in
undifferentiated neuronal progenitor cells [21,22,23]. Although
Figure 3. Differentiation of hNPs into neuronal subtypes after 3 weeks of maturation. A) Cells were immunopositive for ChAT,
demonstrating that the majority of hNPs have the potential to become cholinergic neurons. B) 5HT expression was detected in a subset of cells,
demonstrating that hNPs have the potential to become serotonergic neurons. C) GABAA receptor a1 expression was detected in a subset of cells,
demonstrating the ability to become GABA-responsive neurons. D) TH expression was detected in a subset of cells, demonstrating the ability to
become dopaminergic neurons. E) DARPP32 expression was detected in a subset of cells, demonstrating the ability to become striatal interneurons.
F) Few GFAP positive cells were identified in matured cultures.
doi:10.1371/journal.pone.0020692.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20692Musashi-1and nestin are also expressed in neural progenitor cells,
which have the potential to differentiate into both neuronal and
glial cell types, expression of TUJ1 and doublecortin by hNPs
demonstrates their neuronal progenitor phenotype. Immunocyto-
chemical staining with the oligodendroglial lineage marker O4 and
the astrocyte marker GFAP indicated limited expression in end-
stage cultures, consistent with a high purity neuronal progenitor
population. Furthermore, when allowed to spontaneously differ-
entiate, hNPs generated cholinergic, serotonergic, dopaminergic
and/or noradrenergic, and medium spiny striatal neuronal
Figure 4. RNA expression of matured cultures is consistent with a neuronal lineage. A) Several neurogenic genes were up-regulated after
3 weeks of maturation, as compared to undifferentiated hNPs. B) S100A6 and SOX8 genes, which are often expressed in glial cells, were down-
regulated in the matured cultures, as compared to undifferentiated hNPs.
doi:10.1371/journal.pone.0020692.g004
Figure 5. Differentiation of hNPs 3 months after transplantation to spinal cord injury sites. A) Human nuclei-positive cells (green)
expressed TUJ1 (red), consistent with a neuronal phenotype. B) Human nuclei-positive cells (green) expressed doublecortin (red), consistent with a
young neuronal phenotype. C) Human nuclei-positive cells (green) expressed p75 (red), consistent with young motor, sensory and sympathetic
neurons. D) Human nuclei-positive cells (green) expressed GAD 65–67 (red), consistent with an interneuronal phenotype. E) Human nuclei-positive
cells (brown) expressed ChAT (gray), consistent with a cholinergic phenotype (nuclear counterstain in purple). F) Human specific NCAM (green) and
synaptophysin (red) immunolabeling suggests integration of transplanted cells with the host environment.
doi:10.1371/journal.pone.0020692.g005
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20692sub-types. Manipulation of the culture environment during
differentiation of hNPs altered the percentage of neuronal subtype
derivates. Removal of the caudalizing agent RA concurrent with
alteration of growth factors involved in brain phenotype
specification resulted in differentiation of 5HT
+/ChAT
+ cells
similar to those of the raphe dorsalis, DARPP32
+ cells similar to
those of the striatum, and TH
+ cells similar to those of the
nigrostriatal pathway. These data suggests that hNPs are an
important tool for the discovery of novel targets and factors that
influence neural sub-type differentiation. Glial cells remained
absent or minimal in the manipulated culture conditions,
confirming the restriction of hNPs to the neuronal lineage.
The differentiation of transplanted cells is dictated by their innate
differentiation potential, as well as the environmental signals and
cellular deficiencies at the site of implantation [24]. Transplantation
of hNPs into the injured adult spinal cord resulted in differentiation
to neuronal phenotypes. TUJ1 and doublecortin immunolabeling
demonstrated that hNPs retained their neuronal identity. Some
human cells expressed the p75 neurotrophin receptor indicating
young motor, sensory and sympathetic neuronal phenotypes, while
others expressed GAD 65–67 and ChAT indicating interneurons
and cholinergic neurons respectively [25]. The injured spinal cord is
thought to be innately gliogenic, as transplantation of multipotent
neural stem cells [26] or spinal cord progenitor cells [27,28,29]
results in glial differentiation, even when they are primed to become
cholinergic neurons [30]. Thus, these data indicate that transplant-
ed hNPs retain their neuronal differentiation potential within a
gliogenic environment.
These data demonstrate the production of hNPs in large
quantity and high purity from hESCs in serum-free and feeder-
free conditions. This cell population is ideally suited for neuronal
screening and neuronal developmental studies, as well as
therapeutic strategies addressing diseases and conditions charac-
terized by the loss of neurons. Importantly, this cell population
represents a starting point for the directed differentiation of
neuronal sub-types.
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